Bristol-Myers Agrees To Expensive Buyout Of Amylin: Stay Away
by Stone Fox Capital
Last week, Bristol-Myers Squibb (BMY) announced an additional $3B buyback program (see article here on avoiding stock) that signaled to investors to be cautious. While the amount sounded significant, the details suggested the buyback wouldn't amount to much more than 1.5% of the outstanding stock each year. read more »
Why are you receiving this? You subscribed to real-time article alerts at Seeking Alpha.
If this email was forwarded to you and you wish to subscribe to this email, click here.
Manage your emails:
I'm no longer following BMY: unsubscribe from all BMY email alerts
This type of alert isn't helpful to me: unsubscribe from article alerts on BMY
I'm getting too many emails: manage your email alert choices
Get alerts on additional tickers and manage all your email alert choices here
To ensure you receive these emails in the future, please add account@seekingalpha.com to your address book, contacts or list of safe senders.
Sent by Seeking Alpha, 345 7th Ave. Suite 1400 New York, NY 10001
